Rectal Cancer


Genetic Factors and Colorectal Cancer: Know Your Risk (March 10, 2017)

Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss... Continue Reading

Proton Beam Therapy may Improve Outcomes for Rectal Cancer (March 6, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Innovative Colorectal Cancer Screening Methods for Remote Areas (March 3, 2017)

Colorectal cancer is the second-leading cause of cancer-related death in the United States, despite the fact that more than half of these deaths are avoidable with regular screenings. In fact, with screening,... Continue Reading

Cancers Caught During Screening Colonoscopy are More Survivable (March 2, 2017)

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test. The study, “Survival... Continue Reading

Pass It On: It’s Colorectal Cancer Awareness Month (March 1, 2017)

The colon and rectum are parts of the digestive system, and make up the large intestine. Most of the large intestine is made up of the colon, a muscular tube about five feet long, with the rectum making... Continue Reading

Many Early Onset Colon Cancers are Caused by Genetic Mutations Passed Through Families (January 12, 2017)

One in every six colorectal cancer patients (16 percent) diagnosed under age 50 has at least one inherited genetic mutation that increases his or her cancer risk and many of these mutations could go undetected... Continue Reading

NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer (December 21, 2016)

SIR-Spheres® Y-90 microspheres have just been added as a new treatment option in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for colon cancer... Continue Reading

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to... Continue Reading

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (May 11, 2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor... Continue Reading

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (May 9, 2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent... Continue Reading

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The... Continue Reading

Colorectal Cancer: Year in Review (February 3, 2016)

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the... Continue Reading

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS